Atlas Trials

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Clinical trial NCT03093428 · COMPLETED

Trial details

NCT number
NCT03093428
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer
Start date
2017-06-09
Primary completion
2020-04-09
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.